Back to Blog
Peptide Science••10 min read
Retatrutide Phase 3 Results: 28.7% Body Weight Reduction Sets a New Standard
Phase 3 trial data is in: retatrutide delivers 28.7% average body weight reduction, outpacing every approved GLP-1 therapy. The numbers tell a clear story about where metabolic medicine is heading.
PeptIQ Research Team
Editorial
#phase-3-trial#glucagon#weight loss#clinical data#GLP-1#metabolic health#retatrutide#GIP#2026
Track Your Peptide Protocols
Use PeptIQ to log injections, calculate doses, access our peptide library, and optimize your protocols.
Download PeptIQ
